230 related articles for article (PubMed ID: 26459801)
1. Targeting the ∆133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells.
Nutthasirikul N; Hahnvajanawong C; Techasen A; Limpaiboon T; Leelayuwat C; Chau-In S; Jearanaikoon P
Int J Oncol; 2015 Dec; 47(6):2153-64. PubMed ID: 26459801
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.
Intuyod K; Saavedra-García P; Zona S; Lai CF; Jiramongkol Y; Vaeteewoottacharn K; Pairojkul C; Yao S; Yong JS; Trakansuebkul S; Waraasawapati S; Luvira V; Wongkham S; Pinlaor S; Lam EW
Cell Death Dis; 2018 Dec; 9(12):1185. PubMed ID: 30538221
[TBL] [Abstract][Full Text] [Related]
3. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
4. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
5. Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
Zeekpudsa P; Kukongviriyapan V; Senggunprai L; Sripa B; Prawan A
J Exp Clin Cancer Res; 2014 Jan; 33(1):11. PubMed ID: 24460787
[TBL] [Abstract][Full Text] [Related]
6. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma.
Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Srinontong P; Ratasuwan P; Narong K; Nielsen PS; Maekawa Y
Int J Cancer; 2016 Jan; 138(2):396-408. PubMed ID: 26312563
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
Ren HY; Chen B; Huang GL; Liu Y; Shen DY
Mol Med Rep; 2016 Oct; 14(4):3602-8. PubMed ID: 27599527
[TBL] [Abstract][Full Text] [Related]
8. Thymosin β10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma.
Sribenja S; Natthasirikul N; Vaeteewoottacharn K; Sawanyawisuth K; Wongkham C; Jearanaikoon P; Wongkham S
Ann Hepatol; 2016; 15(4):577-85. PubMed ID: 27236157
[TBL] [Abstract][Full Text] [Related]
9. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
[TBL] [Abstract][Full Text] [Related]
10. Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma.
Nutthasirikul N; Limpaiboon T; Leelayuwat C; Patrakitkomjorn S; Jearanaikoon P
Int J Oncol; 2013 Apr; 42(4):1181-8. PubMed ID: 23404110
[TBL] [Abstract][Full Text] [Related]
11. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX
World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase.
Klinhom-On N; Seubwai W; Sawanyawisuth K; Obchoei S; Mahalapbutr P; Wongkham S
Life Sci; 2021 Dec; 286():120072. PubMed ID: 34688691
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents.
Samatiwat P; Prawan A; Senggunprai L; Kukongviriyapan U; Kukongviriyapan V
Tumour Biol; 2016 Aug; 37(8):11495-507. PubMed ID: 27015836
[TBL] [Abstract][Full Text] [Related]
14. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells.
Klungsaeng S; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Am J Chin Med; 2020; 48(6):1475-1489. PubMed ID: 32907364
[TBL] [Abstract][Full Text] [Related]
15. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway.
Ge X; Wang Y; Li Q; Yu H; Ji G; Miao L
Oncol Rep; 2013 Jul; 30(1):448-54. PubMed ID: 23619566
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Yin Y; Zhang M; Dorfman RG; Li Y; Zhao Z; Pan Y; Zhou Q; Huang S; Zhao S; Yao Y; Zou X
Cell Death Dis; 2017 Jun; 8(6):e2856. PubMed ID: 28569784
[TBL] [Abstract][Full Text] [Related]
17. TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells.
Sriraksa R; Limpaiboon T
Asian Pac J Cancer Prev; 2015; 16(16):6991-6. PubMed ID: 26514480
[TBL] [Abstract][Full Text] [Related]
18. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma.
Koprowski S; Sokolowski K; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2015 Oct; 198(2):434-40. PubMed ID: 25890434
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer activity of asiatic acid against human cholangiocarcinoma cells through inhibition of proliferation and induction of apoptosis.
Sakonsinsiri C; Kaewlert W; Armartmuntree N; Thanan R; Pakdeechote P
Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):28-33. PubMed ID: 30084792
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
